News

A 58-year-old kidney transplant patient developed autoimmune hemolytic anemia (AIHA) three days after receiving an influenza vaccine, a case study reports. The case highlights the importance of educating patients to report any unusual symptoms after vaccination. The study, “Autoimmune Hemolytic Anemia in a Renal Transplant Patient Following…

The investigational therapy sutimlimab prevented hemolysis, significantly increased hemoglobin, and improved the quality of life in patients with cold agglutinin disease (CAD), according to data from a Phase 3 clinical trial. The results will be presented at the Annual Meeting of the American Society of Hematology in December, in…

Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…

Cold agglutinin disease (CAD) patients have an increased risk of developing blood clots compared to the general population, a retrospective Danish study shows. The findings of the study, “Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease” were published recently in the journal Blood Advances. In…

Restricted blood flow, or ischemia, in the nose of a cold agglutinin disease (CAD) patient can be successfully treated using a combination that includes aspirin, heparin, nitroglycerin ointment, and hyperbaric oxygen therapy, a case report details. The report, “A case report of severe nasal…

Arzerra (ofatumumab) may be a promising alternative for the treatment of autoimmune hemolytic anemia (AIHA) in patients who also have systemic lupus erythematosus (SLE) and develop reactions to Rituxan (rituximab), a case report suggests. The study, “Successful treatment of systemic lupus erythematosus-related refractory…

To lower the risk of meningitis infection in patients with cold agglutinin disease (CAD) treated with Soliris (eculizumab), a booster given shortly after the first vaccination may be required, a study suggests. Because patients who receive therapies that target the complement system — such as Soliris — are…

New targeted therapy options are needed for patients who develop autoimmune hemolytic anemia (AIHA) following a stem cell transplant, a review study says. The study, “Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives,” was published in the Journal of Blood Medicine. AIHA…

Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board of directors. “The pace of discovery in rare diseases has gone from brisk to hypersonic,” Summar told Bionews Services, publisher…

Immune rejection and half-matched donors are risk factors for developing autoimmune hemolytic anemia (AIHA) following blood cancer-treating stem cell transplants, a study found. Titled “Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: A southern China multicenter experience,” the study was published in the…